Teledyne Technologies (NYSE: TDY) has entered into a definitive agreement to acquire Varex Imaging (NASDAQ: VREX) in an all-cash transaction valued at approximately $1.1 billion. Under the terms, Varex shareholders will receive $18.90 per share, a premium of about 52% over the company's closing price on August 7. The offer price represents roughly 1.3 times the midpoint of Varex's fiscal 2026 revenue guidance, which stands at $870 million.
The acquisition is expected to close in early 2027, subject to customary regulatory approvals and the approval of Varex shareholders. The boards of both companies have unanimously approved the transaction.
Strategic Fit and Portfolio Expansion
The deal is a strategic move for Teledyne, which already produces X-ray detectors but lacks Varex's specialized high-radiation devices used in oncology. "While Teledyne produces X-ray detectors, we do not provide detectors suited for high-radiation environments such as oncology, as does Varex," said Robert Mehrabian, Executive Chairman of Teledyne. Varex's product line includes X-ray tubes, digital detectors, and imaging software, serving medical, cargo inspection, and industrial applications.
Varex CEO Sunny Sanyal highlighted the complementary nature of the combination, stating, "Teledyne's product range is a natural match for our X-ray technologies, and its backing will enable us to speed up the adoption of our advanced imaging solutions, as well as the creation of next-generation products."
Financial Details and Valuation
The enterprise value of approximately $1.1 billion includes Varex's net debt of about $263 million, as reported in its most recent full quarterly filing. Based on the latest diluted share count of 41.9 million shares, the equity value is approximately $792 million. The remaining difference accounts for equity awards and other adjustments.
At 1.3 times the revenue midpoint, the valuation is considered modest for a niche imaging company. However, the premium reflects the strategic value Teledyne sees in Varex's technology and market position.
Market Reaction and Analyst Perspective
Shares of Varex surged 48.5% on Monday, closing just below the offer price, a typical reaction that reflects the remaining deal risk. The offer exceeds the most recent price targets from analysts at B. Riley ($18.00), Oppenheimer ($18.00), and Jefferies ($14.50). The average target among five analysts was $18.00, with a range of $12 to $22.
The market's positive response indicates recognition of the deal's value. For Varex shareholders, the offer delivers immediate value that was not anticipated in pre-deal price targets. For Teledyne, the acquisition adds a complementary product line at a reasonable multiple.
Financial Health and Capacity
Teledyne reported $1.663 billion in revenue and $284.7 million in free cash flow for the second quarter of 2026. Its Digital Imaging segment, which aligns closely with Varex's products, accounted for 52% of total revenue. The company's leverage stands at 1.1 times, indicating ample capacity to finance the deal.
Varex, meanwhile, reported adjusted earnings per share of $0.31, beating the LSEG consensus of $0.21, and generated $21 million in operating cash flow for the quarter. However, the company faces ongoing challenges from supply-chain disruptions and sluggish demand in China, as noted in its latest report.
Risks and Outlook
The deal is subject to shareholder and regulatory approvals, and the extended timeline to early 2027 introduces risks related to China demand, supply-chain costs, and integration execution. Investors will closely monitor the merger filing and shareholder vote, as well as any additional details on expected synergies.
Overall, the acquisition positions Teledyne to strengthen its imaging portfolio and expand into high-growth oncology applications, while providing Varex shareholders with a substantial premium to the market price.
